Factors influencing patient’s outcome
| Risk factors . | n (%) . | 2-y PFS, % (95% CI) . | PFS . | 2-y OS, % (95% CI) . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariable analysis . | Univariate analysis . | Multivariable analysis . | ||||||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | ||||
| Age, y | |||||||||||
| >50 | 272 (41) | 82 (76.8-86.1) | 1.17 (0.8-1.6) | .36 | 89.9 (85.5-93.0) | 1.42 (0.9-2.2) | .13 | ||||
| ≤50 | 398 (59) | 83.9 (79.9-87.1) | 92.1 (89.0-94.4) | ||||||||
| Sex | |||||||||||
| Male | 373 (56) | 82.4 (78.1-85.9) | 1.17 (0.8-1.6) | .36 | 91.9 (88.5-94.3) | 0.96 (0.6-1.5) | .88 | ||||
| Female | 297 (44) | 84 (79.3-87.7) | 90.5 (86.4-93.4 | ||||||||
| ECOG | |||||||||||
| ≥2 | 94 (14) | 74.1 (63.9-81.8) | 1.68 (1.1-2.5) | .021 | 84.1 (74.6-90.3) | 2.22 (1.3-3.7) | .005 | ||||
| 0-1 | 575 (86) | 84.5 (81.3-87.3) | 92.4 (89.8-94.3) | ||||||||
| Ann Arbor stage | |||||||||||
| III-IV | 552 (82) | 80.6 (77.0-83.7) | 3.78 (1.8-7.7) | <.001 | 3.71 (1.7-8.0) | <.001 | 89.5 (86.6-91.9) | 8.62 (2.1-35.3) | <.001 | ||
| I-II | 118 (18) | 94.9 (89.0-97.7) | 99.1 (94.0-99.9) | ||||||||
| LDH | |||||||||||
| Elevated | 487 (73) | 83.6 (80-86.6) | 0.94 (0.6-1.4) | .73 | 91.0 (88.0-93.2) | 1.16 (0.7-2.0) | 0.57 | ||||
| Normal | 183 (27) | 81.7 (75.3-86.6) | 92.1 (86.9-95.2) | ||||||||
| aa-IPI | |||||||||||
| 2-3 | 383 (58) | 80.8 (76.4-84.4) | 1.46 (1.0-2.1) | .034 | 88.8 (85.0-91.6) | 2.07 (1.2-3.5) | .003 | 3.91 (1.7-8.8) | .001 | ||
| 0-1 | 282 (42) | 86 (81.3-89.6) | 94.5 (91.0-96.6) | ||||||||
| Bulk, cm | |||||||||||
| ≥10 | 213 (32) | 78.3 (72.1-83.3) | 1.42 (1.0-2.0) | .05 | 1.49 (1.0-2.2) | .039 | 89.2 (84.0-92.7) | 1.45 (0.9-2.3) | .12 | ||
| <10 | 457 (68) | 85.4 (81.7-88.3) | 92.2 (89.3-94.4) | ||||||||
| Hans score | |||||||||||
| Non-GC | 250 (47) | 81.9 (76.6-86.2) | 1.15 (0.8-1.7) | .46 | 89.6 (85.0-92.9) | 1.39 (0.8-2.3) | .20 | ||||
| GC | 282 (53) | 83.9 (79-87.7) | 93.0 (89.3-95.5) | ||||||||
| BCL2 | |||||||||||
| ≥70% | 391 (73) | 80.6 (76.3-84.2) | 1.99 (1.2-3.3) | .004 | 90.6 (87.2-93.2) | 1.84 (0.9-3.6) | .064 | 2.41 (1.0-5.7) | .047 | ||
| <70% | 148 (27) | 89.7 (83.5-93.7) | 94.3 (89.0-97.1) | ||||||||
| MYC | |||||||||||
| ≥40% | 241 (52) | 81.3 (75.8-85.7) | 1.39 (0.9-2.1) | .12 | 89.8 (85.1-93.0) | 1.31 (0.7-2.3) | .34 | ||||
| <40% | 221 (48) | 86.2 (80.8-90.1) | 92.9 (88.5-95.7) | ||||||||
| DE Myc/Bcl2 | |||||||||||
| Yes | 183 (41) | 79.8 (73.2-84.9) | 1.46 (0.96-2.2) | .075 | 88.7 (83.1-92.6) | 1.41 (0.8-2.5) | .23 | ||||
| No | 267 (59) | 85.9 (81.1-89.6) | 92.6 (88.6-95.2) | ||||||||
| Treatment arm | |||||||||||
| Obinutuzumab | 336 (50) | 83.2 (78.7-86.8) | 1.03 (0.7-1.4) | .87 | 0.95 (0.7-1.4) | .77 | 90.7 (87.0-93.4) | 0.96 (0.6-1.5) | .86 | 0.89 (0.5-1.6) | .69 |
| Rituximab | 334 (50) | 83 (78.5-86.7) | 91.8 (88.1-94.3) | ||||||||
| Chemotherapy | |||||||||||
| CHOP | 339 (51) | 82.7 (78.2-86.4) | 1.14 (0.8-1.6) | .46 | 1.06 (0.7-1.5) | .76 | 92.0 (88.4-94.5) | 1.10 (0.7-1.8) | .70 | 0.85 (0.5-1.5) | .59 |
| ACVBP | 324 (49) | 84.7 (80.3-88.2) | 91.6 (87.9-94.2) | ||||||||
| PET2/PET4 | |||||||||||
| PET4+ | 93 (16) | 62 (51.3-71.0) | 3.44 (2.3-5.1) | <.001 | 3.17 (2.1-4.7) | <.001 | 83.1 (73.0-89.7) | 2.49 (1.4-4.5) | .005 | 3.61 (1.9-6.8) | <.001 |
| PET2− or PET+/PET4− | 493 (84) | 89 (85.8-91.4) | 94.5 (92.1-96.3) | ||||||||
| Risk factors . | n (%) . | 2-y PFS, % (95% CI) . | PFS . | 2-y OS, % (95% CI) . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariable analysis . | Univariate analysis . | Multivariable analysis . | ||||||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | ||||
| Age, y | |||||||||||
| >50 | 272 (41) | 82 (76.8-86.1) | 1.17 (0.8-1.6) | .36 | 89.9 (85.5-93.0) | 1.42 (0.9-2.2) | .13 | ||||
| ≤50 | 398 (59) | 83.9 (79.9-87.1) | 92.1 (89.0-94.4) | ||||||||
| Sex | |||||||||||
| Male | 373 (56) | 82.4 (78.1-85.9) | 1.17 (0.8-1.6) | .36 | 91.9 (88.5-94.3) | 0.96 (0.6-1.5) | .88 | ||||
| Female | 297 (44) | 84 (79.3-87.7) | 90.5 (86.4-93.4 | ||||||||
| ECOG | |||||||||||
| ≥2 | 94 (14) | 74.1 (63.9-81.8) | 1.68 (1.1-2.5) | .021 | 84.1 (74.6-90.3) | 2.22 (1.3-3.7) | .005 | ||||
| 0-1 | 575 (86) | 84.5 (81.3-87.3) | 92.4 (89.8-94.3) | ||||||||
| Ann Arbor stage | |||||||||||
| III-IV | 552 (82) | 80.6 (77.0-83.7) | 3.78 (1.8-7.7) | <.001 | 3.71 (1.7-8.0) | <.001 | 89.5 (86.6-91.9) | 8.62 (2.1-35.3) | <.001 | ||
| I-II | 118 (18) | 94.9 (89.0-97.7) | 99.1 (94.0-99.9) | ||||||||
| LDH | |||||||||||
| Elevated | 487 (73) | 83.6 (80-86.6) | 0.94 (0.6-1.4) | .73 | 91.0 (88.0-93.2) | 1.16 (0.7-2.0) | 0.57 | ||||
| Normal | 183 (27) | 81.7 (75.3-86.6) | 92.1 (86.9-95.2) | ||||||||
| aa-IPI | |||||||||||
| 2-3 | 383 (58) | 80.8 (76.4-84.4) | 1.46 (1.0-2.1) | .034 | 88.8 (85.0-91.6) | 2.07 (1.2-3.5) | .003 | 3.91 (1.7-8.8) | .001 | ||
| 0-1 | 282 (42) | 86 (81.3-89.6) | 94.5 (91.0-96.6) | ||||||||
| Bulk, cm | |||||||||||
| ≥10 | 213 (32) | 78.3 (72.1-83.3) | 1.42 (1.0-2.0) | .05 | 1.49 (1.0-2.2) | .039 | 89.2 (84.0-92.7) | 1.45 (0.9-2.3) | .12 | ||
| <10 | 457 (68) | 85.4 (81.7-88.3) | 92.2 (89.3-94.4) | ||||||||
| Hans score | |||||||||||
| Non-GC | 250 (47) | 81.9 (76.6-86.2) | 1.15 (0.8-1.7) | .46 | 89.6 (85.0-92.9) | 1.39 (0.8-2.3) | .20 | ||||
| GC | 282 (53) | 83.9 (79-87.7) | 93.0 (89.3-95.5) | ||||||||
| BCL2 | |||||||||||
| ≥70% | 391 (73) | 80.6 (76.3-84.2) | 1.99 (1.2-3.3) | .004 | 90.6 (87.2-93.2) | 1.84 (0.9-3.6) | .064 | 2.41 (1.0-5.7) | .047 | ||
| <70% | 148 (27) | 89.7 (83.5-93.7) | 94.3 (89.0-97.1) | ||||||||
| MYC | |||||||||||
| ≥40% | 241 (52) | 81.3 (75.8-85.7) | 1.39 (0.9-2.1) | .12 | 89.8 (85.1-93.0) | 1.31 (0.7-2.3) | .34 | ||||
| <40% | 221 (48) | 86.2 (80.8-90.1) | 92.9 (88.5-95.7) | ||||||||
| DE Myc/Bcl2 | |||||||||||
| Yes | 183 (41) | 79.8 (73.2-84.9) | 1.46 (0.96-2.2) | .075 | 88.7 (83.1-92.6) | 1.41 (0.8-2.5) | .23 | ||||
| No | 267 (59) | 85.9 (81.1-89.6) | 92.6 (88.6-95.2) | ||||||||
| Treatment arm | |||||||||||
| Obinutuzumab | 336 (50) | 83.2 (78.7-86.8) | 1.03 (0.7-1.4) | .87 | 0.95 (0.7-1.4) | .77 | 90.7 (87.0-93.4) | 0.96 (0.6-1.5) | .86 | 0.89 (0.5-1.6) | .69 |
| Rituximab | 334 (50) | 83 (78.5-86.7) | 91.8 (88.1-94.3) | ||||||||
| Chemotherapy | |||||||||||
| CHOP | 339 (51) | 82.7 (78.2-86.4) | 1.14 (0.8-1.6) | .46 | 1.06 (0.7-1.5) | .76 | 92.0 (88.4-94.5) | 1.10 (0.7-1.8) | .70 | 0.85 (0.5-1.5) | .59 |
| ACVBP | 324 (49) | 84.7 (80.3-88.2) | 91.6 (87.9-94.2) | ||||||||
| PET2/PET4 | |||||||||||
| PET4+ | 93 (16) | 62 (51.3-71.0) | 3.44 (2.3-5.1) | <.001 | 3.17 (2.1-4.7) | <.001 | 83.1 (73.0-89.7) | 2.49 (1.4-4.5) | .005 | 3.61 (1.9-6.8) | <.001 |
| PET2− or PET+/PET4− | 493 (84) | 89 (85.8-91.4) | 94.5 (92.1-96.3) | ||||||||
HR, hazard ratio. See Table 1 for expansion of other abbreviations.